Eli Lilly and Company (LLY)
Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Eli Lilly and Company (LLY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website
Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.
Eli Lilly cuts price of Zepbound in heightened weight-loss drug competition
Eli Lilly and Co (NYSE:LLY) said on Monday it is lowering the cash prices of its weight-loss drug Zepbound, marking the latest move in a growing price battle with rival Novo Nordisk. The US pharmaceutical giant said single-dose vials of Zepbound will now be available on its direct-to-consumer platform, LillyDirect, at reduced prices.
Eli Lilly cuts Zepbound price to widen access for obesity drug
Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S. patients, as demand for weight-loss therapies surge.
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
Eli Lilly said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect. Starting Dec. 1, cash-paying patients with a valid prescription can pay $299 to $449 per month for Zepbound vials on LillyDirect, depending on the dose, down from a previous range of $349 to $499 per month.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026
Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.
A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling
In the last part of November 2025, Eli Lilly and Company NYSE: LLY shattered a historic ceiling. The Indianapolis-based drugmaker became the first pharmaceutical company to reach a market capitalization of $1 trillion.
Eli Lilly Stock Value Tops $1 Trillion. Learn Why And If To Buy $LLY
Eli Lilly stock has risen 36% this year to reach a $1 trillion market capitalization – the first health-care company to reach this milestone, according to CNBC.
Eli Lilly: The Weight-Loss Leader With More Upside If Execution Holds
Eli Lilly has surged 47% since my last article, exceeding my previous $800 price target and reaching all-time highs near $1,030. LLY's leadership in the obesity treatment market continues to drive top- and bottom-line growth, reinforcing its bullish long-term outlook. The company offers stability amid market volatility, with strong U.S. dominance, premium margins, and potential undervaluation if growth targets are met.
When Investors Panic, I Buy Eli Lilly
Eli Lilly delivered 54% revenue growth in Q3 2025, raised full-year guidance, and remains a defensive haven amid market volatility. LLY's obesity and diabetes franchise, led by Zepbound, Mounjaro, and upcoming orforglipron, drives robust international growth and pipeline expansion. Massive manufacturing investments and a deep late-stage pipeline, including orforglipron and retatrutide, reinforce LLY's durable competitive moat.
Eli Lilly becomes first health-care company to hit $1 trillion
Silicon Valley's giants crowd the list of the world's most valuable companies, but drugmaker Eli Lilly is hot on their heels. The company topped a market capitalization of one trillion dollars on Friday, becoming the first business in the health industry to hit that milestone.
